Thymosin Alpha-1 stands apart from most peptides in the research scene for one simple reason: it has real human clinical trials, and in many countries it is an actual approved medicine. It is a 28-amino-acid peptide (a small protein) that the thymus — a gland behind the breastbone that trains immune cells — naturally produces. Its job is to help balance the immune system. The synthetic drug version is sold as Zadaxin.
In plain terms: an immune-balancing peptide the body already makes, and one of the few in this space with genuine human evidence behind it.
What it is
The thymus releases a family of signalling molecules called thymosins. Thymosin Alpha-1 is one fragment of that family, purified and identified decades ago, then made synthetically as an identical 28-amino-acid peptide. Because it is a copy of something the body produces, it is an immune modulator rather than a foreign stimulant.
The brand name to know is Zadaxin. That is the pharmaceutical form of Thymosin Alpha-1, approved and marketed in dozens of countries3.
How it works: modulation, not just boosting
The word to hold onto is modulation. Thymosin Alpha-1 does not simply crank the immune system up; it helps it mature and balance. It supports the development of T cells (immune cells that coordinate and carry out attacks) and helps steer the response.
Part of that action runs through Toll-like receptors — sensors the immune system uses to recognise threats. By signalling through these receptors, Thymosin Alpha-1 can nudge immune cells toward a more organised, balanced response3.
In plain terms: it acts like a coach for the immune system, helping it respond in a coordinated way rather than a scattered one.
Pharmacokinetics: short half-life, repeated dosing
Thymosin Alpha-1 clears the blood quickly. Its plasma half-life (the time for half a dose to leave the circulation) is roughly 2 hours in humans after a subcutaneous injection. Because it does not linger, the clinical trials gave it as repeated doses — typically several times a week — rather than the once-weekly rhythm of a long-acting drug.
In plain terms: it comes and goes fast, so studies dosed it often.
What the trials actually found
This is the section that separates Thymosin Alpha-1 from the preclinical crowd: much of its evidence is human. Note the model in each row.
| Trial | Model / level | Key result | Year |
|---|---|---|---|
| Maio et al.1 | Humans (RCT, n=488) | Added Thymosin Alpha-1 to chemotherapy for metastatic melanoma; the peptide-containing arms showed a survival signal worth further study | 2010 |
| Wu et al. — ETASS2 | Humans (RCT, n=361) | In severe sepsis, lower 28-day death rate versus control (relative risk ~0.73) | 2013 |
| Camerini & Garaci — review3 | Review (human data) | Summarises chronic hepatitis B/C use and approval in more than 30 countries | 2015 |
Read these as what they are: genuine human trials, but not perfect ones. The melanoma study was a large randomised trial that suggested a benefit from adding the peptide, without settling the question1. The sepsis trial (ETASS) was single-blind and run in China, and it reported a real reduction in short-term deaths2. The hepatitis evidence is the oldest and most established — the basis for its approval in many countries for chronic hepatitis B3.
In plain terms: this is the rare peptide where "human trial" is an accurate label, not marketing — while still being honest that the trials are mixed and mostly outside the US regulatory system.
Regulatory status
Here is the nuanced honesty. Thymosin Alpha-1 is not FDA-approved in the United States. But it is an approved, marketed medicine (as Zadaxin) in dozens of other countries, used mainly for chronic hepatitis B and C and as immune support alongside other treatments3. So describing it simply as "unapproved" is wrong, and describing it as "FDA-approved" is also wrong. The accurate statement: approved in many countries, not in the US. This page describes that status and the studies — not how to use it — and takes no position on sourcing.
Handling and format
Zadaxin and research-grade Thymosin Alpha-1 are supplied as a lyophilised (freeze-dried) powder reconstituted before use, kept refrigerated once mixed — standard peptide handling. The clinical protocols dosed it subcutaneously several times weekly, reflecting the short half-life.
Latest research
- The hepatitis B evidence remains the backbone of its approvals, built over decades and summarised in the 2015 review3.
- The 2013 ETASS sepsis trial is the most-cited modern result — a reduction in short-term mortality in severe sepsis that spurred follow-up immunotherapy research2.
- Interest surged around immune modulation in serious infection. Thymosin Alpha-1 was studied during the COVID-19 period as an immune-balancing add-on, keeping it an active research topic rather than a historical one. We update this section as controlled results report.
The short version
Thymosin Alpha-1 (Zadaxin) is a 28-amino-acid peptide the thymus makes to balance the immune system. It is one of the few compounds in this space with real human trials — in chronic hepatitis B and C, severe sepsis, and cancer add-on therapy — and it is an approved medicine in dozens of countries, though not in the US. Its half-life is short (~2 hours), so trials dosed it repeatedly. Educational overview only, not medical advice. For contrast with preclinical-only peptides, see what are research peptides.